Covidien, a provider of healthcare products, has established Covidien Ventures, a corporate venture capital function. Covidien Ventures will invest in areas of strategic importance to the company with the goal of providing early exposure to innovative technologies and enhancing market intelligence in healthcare products.
Subscribe to our email newsletter
Covidien Ventures will be managed by Daniel Sheehan, vice president of Corporate Venture Capital, who recently joined Covidien from Affinity Capital Management.
Mr Sheehan, who has 20 years of experience in venture capital, business development and investment banking, will direct the new fund and lead the investment process for Covidien.
Amy Wendell, senior vice president of corporate strategy and business development, said: “Covidien Ventures will allow us to make early-stage investments and investigate emerging technologies in the healthcare areas of interest to Covidien. This exposure could potentially lead to our acquiring technology, intellectual property or start-up companies to expand our product portfolio and accelerate business growth.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.